In Brief: Autonomous v. Pillar Point Partners/Visx
This article was originally published in The Gray Sheet
Autonomous v. Pillar Point Partners/Visx: Autonomous Technologies Corp. files patent suit seeking declaratory judgment that its T-PRK (Tracker-assisted Photorefractive Keratectomy) system does not infringe Pillar Point patents in the U.S. or Visx PRK patents in Canada. In addition, the U.S. action seeks a ruling that all Pillar Point patents are unenforceable. ATC also "plans to vigorously defend against any other allegations of infringement asserted against" the T-PRK system, including a suit filed in the U.K. by Visx...
You may also be interested in...
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.